Ferring Pharmaceuticals initiates phase III trials of elobixibat
The two studies, Echo 1 and Echo 2, which will be conducted at close to 200 sites worldwide, will enroll nearly 1700 patients. The studies will assess the
The two studies, Echo 1 and Echo 2, which will be conducted at close to 200 sites worldwide, will enroll nearly 1700 patients. The studies will assess the
As per the agreement, ChemRar Ventures will source early and late stage compounds within a certain defined area of Sanofi’s therapeutic interest and negotiating the potential pharma partnering
The collaboration aims to establish integrin peptide therapy as the first-in-class treatment that targets integrin with an oligopeptide to improve the quality of life for patients with risk
The collaboration will focus on the discovery, development and commercialisation of small-molecule therapies directed against three novel targets to treat metabolic diseases specially type 2 diabetes. Abide Therapeutics
The company anticipates that one kilogram of Adva-27a will be sufficient to complete the upcoming IND-Enabling animal toxicity studies and Phase I clinical trials. By completing the animal
Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death. Raptor CEO and
Major changes at the plant comprise upgrades and validation of critical equipment, manufacturing processes, analytical methodology and data collection systems. Vertellus Agriculture & Nutrition Specialties president Bentley Park
The technology designed with air-wheel mixing system enables maximum operation efficiency and requires less space. PBS Bioreactors are scalable from 3lt to 2500lt. PBS Biotech president Brian Lee
The technology to be acquired facilitates rapid assay development and reduced costs for the end user. Co-Diagnostics president Dwight Egan said, "With this technology, we believe our highly
Hyperion Therapeutics president and CEO Donald Santel said that the orphan drug exclusivity further strengthens the protections for Ravicti. "Additionally, as we recently announced, we were issued a